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DERIVING SEVERITY INDEX FOR RHEUMATOID ARTHRITIS FROM 
HEALTH CARE CLAIMS DATA
Baser O1, Gust C2, Akin C3
1STATinMED Research / University of Michigan, Ann Arbor, MI, USA, 2STATinMED 
Research, Ann Arbor, MI, USA, 3STATinMED Research / Brigham and Women’s Hospital, 
Ann Arbor, MI, USA
OBJECTIVES: Health care claims databases do not contain information about disease 
severity. The goal of this study was to develop a severity index for rheumatoid arthritis 
(SIFRA) for private health care claims data using a previously developed claims-based 
index from the Veteran’s Administration (VA) Health System and rheumatoid arthritis 
medical records-based index of severity (RARBIS). METHODS: We extracted the 
following variables related to rheumatoid arthritis from the claims data: total number 
of synthetic disease-modifying anti-rheumatic drugs (DMARDs), total number of 
biological DMARDs, tests for C-reactive protein (CRP) and erythrocyte sedimentation 
rate (ESR) ordered, rehabilitation visits, rheumatology visits, Felty’s syndrome and 
Sjorgen’s syndrome, pulmonary, soft tissue nodules, joint surgery, number of platelet 
counts and chemical panels ordered, and rheumatoid factors testing. A linear regres-
sion model was used to create the severity score. The severity score was compared 
with RARBIS and currently-used comorbidity scores to proxy severity in outcomes 
research studies related with rheumatoid arthritis. RESULTS: According to the Akaike 
Information Criterion (AIC), Bayesian Information Criterion (BIC), log likelihood 
function, R-squared values and average squared prediction error, SIFRA performed 
better than RARBIS, Charlson Comorbidity Score (CCI), Elixhauser comorbidity score 
and Chronic disease score. Spearman correlation with RARBIS was 0.65 and signiﬁ-
cant. However, the correlation with the Charlson Comorbidity Index (0.1, p = 
0.6521), Elixhauser Index (0.15, p = 0.5312) and Chronic disease score (0.13, p = 
0.6011) were low and insigniﬁcant. CONCLUSIONS: Controlling disease severity is 
crucial in retrospective studies. Comorbidity scores are inadequate to be proxy vari-
able. SIFRA, at least for rheumatoid arthritis, controls for disease severity better than 
any other commonly used measure.
NEUROLOGICAL DISORDERS – Clinical Outcomes Studies
PND1
CLINICAL AND PHARMACY UTILIZATION OUTCOMES WITH BRAND 
TO GENERIC ANTIEPILEPTIC UTILIZATION IN PATIENTS WITH 
EPILEPSY
Erickson SC1, Le L1, Zakharyan A1, Stockl KM1, Solow B1, Harada A1, Ramsey S2
1Prescription Solutions, Irvine, CA, USA, 2Fred Hutchinson Cancer Research Center, 
University of Washington, Seattle, WA, USA
OBJECTIVES: To determine if switching from select branded to generic equivalent 
antiepileptic drug (AED) in patients with epilepsy is associated with adverse outcomes 
or with utilization changes that may proxy for adverse outcomes. METHODS: A 
retrospective cohort study using a large health insurance plan claims database was 
undertaken comparing patients with ICD-9-CM codes of epilepsy or non-febrile 
convulsions who switched from brand to generic equivalent AED after 6 months 
(switch cohort) to those who remained on the brand (non-switch cohort). Potential 
non-switch subjects were matched 1:1 to 745 phenytoin switch patients, 995 lamotrig-
ine switch patients and 399 divalproex switch patients. Outcomes measured included 
the event rate ratio (ERR) of the composite of all-cause emergency department (ED) 
visits or hospitalizations and the incidence rate ratio (IRR) of discontinuation of the 
index AED, change in dose of index AED or addition of another AED. RESULTS: 
The switch vs. non-switch cohorts did not demonstrate differences in ED visits or 
hospitalizations for the studied AEDs (ERR for phenytoin 0.96, 95% CI 0.80–1.16; 
ERR for lamotrigine 0.97, 95% CI 0.80–1.17; ERR for divalproex 0.83, 95% CI 
0.66–1.06). Compared with non-switchers, the phenytoin switch cohort had greater 
incidence of AED utilization changes (IRR 1.85, 95% CI 1.50–2.29). Lamotrigine and 
divalproex showed no differences in AED utilization between the switchers and non-
switchers (IRR for lamotrigine 1.00, 95% CI 0.84–1.19; IRR for divalproex 1.02, 
95% CI, 0.88–1.42). CONCLUSIONS: Lamotrigine or divalproex brand to generic 
switching was not associated with increased incidence of ED visits or hospitalizations 
or utilization changes compared with patients remaining on the branded product. 
Brand to generic switching of phenytoin was not associated with an increase in ED 
visits or hospitalizations but was associated with greater numbers of index drug dis-
continuations, dose changes or therapy augmentations.
PND2
THE VALUE OF A PREDICTIVE DIAGNOSTIC BLOOD TEST IN 
MULTIPLE SCLEROSIS (MS)
Van Hout BA1, Botteman M2, Dukler A3
1University of Shefﬁeld, Shefﬁeld, UK, 2Pharmerit North America, LLC, Bethesda, MD, USA, 
3Glycominds Ltd., Lod, Israel
OBJECTIVES: To assess the cost effectiveness of gMS®Pro EDSS, a test designed to 
identify MS patients with a high likelihood of progressing fast and in need of more 
aggressive treatment. METHODS: A literature-based discrete-event simulation follows 
patients visiting their physicians at deﬁned EDSS score deteriorations. At each visit, 4 
therapies are considered: three less aggressive/less expensive therapies (assumed 
monthly cost of $2,000/patient) and a more aggressive/more expensive therapy 
(assumed monthly cost of $3,000/patient) associated with severe side effects. The more 
agressive therapy is only considered cost effective in fast deteriorating patients. The 
expected cost effectiveness of each therapy was calculated using a Markov model 
(using EDSS scores as health states) and applying a Bayesian updating process con-
sidering the likelihood that the patient is “fast deteriorating” and/or responds to 
therapy. The model compares patients’ costs and quality of life when the gMS®Pro 
EDSS test is used vs. when it is not. The estimated sensitivity and speciﬁcity of 
gMS®Pro EDSS were 65.18% and 84.09%, respectively based on clinical trail results. 
The costs of all non-medication costs were based on Kobelt et al. RESULTS: Using 
the test, in comparison to not using the test, in a MS population containing 25% of 
patients who progress fast results in more frequent (25.18% vs. 24.24%) and earlier 
(2.24 years on average) use of aggressive therapy. The test is estimated to result in a 
gain of 0.11 QALY’s and to be economically dominant up to a price of $2640 (cost 
of medication is estimated to increase by $2984 which is offset by savings of $2704 
of other direct medical costs and $2920 of production losses). CONCLUSIONS: The 
gMS®Pro EDSS is likely to be a cost effective addition in the identiﬁcation of the 
optimal therapy for MS patients.
PND3
GASTROINTESTINAL DISORDERS IN PATIENTS WITH PARKINSON’S 
DISEASE: A DOUBLE-EDGED SWORD
Richy F1, Gunn A1, Makaroff L2, Gervasoni C3, Helmers S4
1UCB Pharma S.A., Brussels, Belgium, 2Business & Decision, Brussels, Belgium, 3Keyrus, 
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OBJECTIVES: A majority of patients with Parkinson’s disease (PD) eventually develop 
gastrointestinal disorders (GID), which can impair the onset of symptom relief by PD 
drugs. There was a need to better understand the rate and consequences of GID 
amongst patients diagnosed with PD. METHODS: A two years matched retrospective 
cohort study was performed in a registered Pharmetrics® datacut, a US claims data-
base containing records on demographics, diagnoses, procedures, provider, prescrip-
tions and claims that span from 2000 to 2008. Patients with at least two prior 
diagnoses of Parkinson’s Disease, with continuous prescriptions of levodopa or dopa-
mine agonists between September 1, 2005 and September 1, 2006 were selected. 
Patients with and without GID were matched by age, gender, comorbidities, and 
treatment regime. Their respective emerging health outcomes were followed-up for 
two years. Outcomes were deﬁned on the basis of a literature review and included 
neuropsychiatric, motor, urogenital disturbances, health care utilization and related 
costs. RESULTS: In the datacut, GID incidence among patients with PD increased 
over time to stabilize at 75% at 92 months. 485 patients with PD and GID were 
matched to 485 controls with PD but without GID. GID was associated with signiﬁ-
cantly higher rates of neuropsychiatric and motor disorders, including psychosexual 
dysfunction (RR = 8, p = 0.05), anxiety (RR = 1.61, p < 0.01), depression (RR = 1.28, 
p = 0.03), ataxia (RR = 1.24, p = 0.03), pain (RR = 1.28, p < 0.01), movement dis-
orders (RR = 1.39, p < 0.01), urinary incontinence (RR = 1.43, p = 0.02), and risk of 
fall (RR = 1.44, p = 0.04). ER admissions (ratio = 1.42, p < 0.01), number of concur-
rent drugs (ratio = 1.06, p = 0.04) and PD and non-PD health care costs (ratios = 1.13 
and 1.12, p < 0.01 respectively) increased during the observation period in the GID 
patients. CONCLUSIONS: GID have a substantial deleterious effect on major PD-
related clinical and societal outcomes. Non oral formulations of PD drugs (apomor-
phine or L-dopa pumps or rotigotine) may offer a good opportunity to bypass 
gastrointestinal tract, and accordingly maximize patient response to treatment.
NEUROLOGICAL DISORDERS – Cost Studies
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ESTIMATED COST SAVINGS WHEN TREATING RESTLESS LEGS 
SYNDROME (RLS) WITH GABAPENTIN ENACARBIL IN THE US
Allen R1, Bharmal M2, Manjunath R3, Calloway M3
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VA, USA, 3GlaxoSmithKline, Research Triangle Park, NC, USA
OBJECTIVES: Estimate total (direct plus indirect) cost savings with 1200 mg of gaba-
pentin enacarbil (GEn), a new RLS therapy. For formulary access, new medications 
must often show cost savings of drug. Before approval, data are hard to generate. This 
study provides one way of generating estimated pre-launch cost savings per patient. 
METHODS: Two data sources are used: pooled efﬁcacy results from two 12-week, 
randomized, double-blind, placebo-controlled trials (Protocol XP052 and XP053, 
Clinical Trials.gov NCT00298623 and NCT00365352) of GEn and resource use/
economic data from a 2007 community survey. The survey collected RLS-related 
ofﬁce (physician, emergency room, hospital) laboratory tests, prescription and non-
prescription medication use. Indirect costs came from the Work Productivity and 
Activity Impairment (WPAI) questionnaire. Severity class costs were derived by using 
the International Restless Legs Syndrome Questionnaire. Estimated savings were 
derived by applying the proportion of patients moving between severity categories to 
cost differences between those categories. RESULTS: A total of 191 patients received 
GEn and completed baseline/Week 12 assessments. From baseline to Week 12, 48.2% 
with moderate RLS severity moved to mild severity, 26.7% moved from severe to mild 
and 8.4% moved from severe to moderate. The mean (SD) 3-month direct RLS-related 
costs among mild, moderate, severe and very severe patients were $48.90 ($113.7), 
$108.60 ($210.2), $264.60 ($391.30) and $428.3 ($689.40), respectively. Mean (SD) 
3-month indirect costs due to RLS-related lost productivity were $460.20 ($838.20), 
$1462.50 ($2513.90), $3699.30 ($3471.60) among mild, moderate and severe 
patients (no very severe reported working). Using sensitivity analyses, the per-patient, 
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3-month, estimated, direct cost savings for treatment with GEn ranged from $94.40 
to $202.80. Similarly, the per-patient indirect cost savings due to improved work 
productivity ranged from $1447.30 to $2587.60. Thus, total 3-month cost savings 
ranged from $1541.70 to $2790.40. CONCLUSIONS: Based on these ﬁndings, the 
estimated annual total treatment cost savings with GEn is approximately $6,000 to 
$11,000 per patient.
PND5
COMPARISON OF DIRECT AND INDIRECT COSTS IN EMPLOYEES WITH 
PAINFUL DIABETIC PERIPHERAL NEUROPATHY TREATED WITH 
PREGABALIN OR DULOXETINE
Margolis J1, Cao Z2, Fowler R3, Harnett J4, Silverman SL5
1Thomson Reuters, Bala Cynwyd, PA, USA, 2Thomson Reuters, Cambridge , MA, USA, 
3Thomson Reuters, Washington, DC, USA, 4Pﬁzer, New York, NY, USA, 5Cedars-Sinai/
UCLA, Beverly Hills, CA, USA
OBJECTIVES: To evaluate the effects on direct and indirect costs of initiating prega-
balin or duloxetine in employees diagnosed with painful diabetic peripheral neuropa-
thy (pDPN). METHODS: Employees (18–64 years old) with a diagnosis of DPN and 
at least one claim for a pDPN-related pain medication were identiﬁed using the 
Thomson Reuters MarketScan® Commercial Claims and Encounters Research Data-
base (2005–2008). Patients were continuously enrolled in the 6-month pre- and 
6-month post-initiation periods. To control for selection bias, propensity scored 
matched pregabalin and duloxetine new starts were evaluated. Key study outcomes 
including imputed medically-related work loss, prescription and health care utiliza-
tion, and associated expenditures were analyzed using bivariate statistics and multi-
variate models in a difference-in-difference approach. RESULTS: A total of 946 
employees with pDPN (473 per group) were identiﬁed. In the pre-index period, there 
were no statistically signiﬁcant differences between groups in age (mean 54.0 ± 5.6 
pregabalin and 53.3 ± 7.5 duloxetine), gender (females 52% pregabalin, 48% dulox-
etine), geographic distribution, insurance plan types, comorbidities, medication use, 
health care resource utilization or health care expenditures. The average number of 
prescriptions in the 6-month post-index period was 2.9 ± 1.9 for pregabalin and 3.1 
± 2.1 for duloxetine. There were no signiﬁcant differences between treatment groups 
for pre-to-post changes in opioid utilization (marginal effect 1.3 percentage points 
fewer pregabalin opioid patients, p = 0.328) as well as the number of pDPN-related 
pain medications (marginal effect 0.108 more medications for pregabalin, p = 0.506). 
The adjusted marginal effects for pre-to-post changes in all-cause health care expen-
ditures ($154 greater increase for pregabalin patients, p = 0.895), pDPN-attributable 
expenditures ($145 greater increase for pregabalin patients, p = 0.359) and indirect 
costs ($458 relative decrease for pregabalin patients, p = 0.324) were not statistically 
signiﬁcant. CONCLUSIONS: There were no signiﬁcant pre-to-post differences 
between pregabalin and duloxetine treatment groups in opioid use, DPN-related pain 
medication use, pDPN-attributable, all-cause and indirect expenditures.
PND6
MODELING THE ESTIMATED COST-SAVINGS OF STRATIFIED CARE 
FOR MIGRAINE HEADACHES FROM A U.S. PERSPECTIVE
Furiak N, Bansal M
Medical Decision Modeling Inc., Indianapolis, IN, USA
OBJECTIVES: To estimate the differences in costs of treating migraine headaches 
employing a stratiﬁed care (STRAT) approach versus the more common stepped care 
(STEP) using MIDAS scores in the U.S. STRAT using MIDAS scores has been shown 
to be cost-effective in other settings. However, STRAT is not widely used in the U.S. 
In this study, a published decision model was adapted to the U.S. setting and the 
differences in costs were evaluated for STEP and STRAT in the U.S. by differentiating 
the patients by MIDAS scores. METHODS: Published values for costs of physician/
specialist visits, over the counter (OTC) analgesics, aspirin+metoclopramide (AM), 
triptans, and hospitalizations were used to create a microsimulation model for a U.S. 
perspective. Therapy effectiveness for OTCs, AM, and triptans by MIDAS scores I, 
II, and III were taken from the published decision tree. In the base-case the proportion 
of MIDAS I, II, and III patients were 5%, 25%, and 70% respectively. STEP patients 
were forced through each phase of therapy regardless of MIDAS score. STRAT 
patients were moved ahead to advanced phases of therapy given higher MIDAS score. 
In the model, a sample of 1000 patients is taken and is distributed according to the 
MIDAS scores. The costs are attached to each node of the treatment algorithm to 
obtain the total costs. RESULTS: Base case results showed that mean annual direct 
medical costs on STEP for the population were $1229 compared to $1088 for STRAT. 
Sensitivity analysis showed that the differences in costs (STEP-STRAT) were $210 for 
a cohort of MIDAS II patients and $142 for a cohort of MIDAS III patients. CON-
CLUSIONS: Model results indicate that STRAT has the potential for cost savings in 
a U.S. setting. Increased awareness and used of STRAT can beneﬁt patients, providers, 
and payers in the treatment of migraine headache.
PND7
THE IMPACT OF SPECIALTY PHARMACY PARTICIPATION ON HEALTH 
CARE COSTS IN A MULTIPLE SCLEROSIS POPULATION USING 
BIOLOGIC DMD THERAPY
Faris RJ1, Steinberg SC2, Bolton C1
1Accredo Health, Memphis, TN, USA, 2Accredo Health and the University of Memphis, 
Memphis, TN, USA
OBJECTIVES: To determine if the pharmacy provider model for patients with relaps-
ing remitting multiple sclerosis (MS) on biologic disease modifying drugs (DMD) 
impacts medical costs. METHODS: A retrospective cohort study design was used. 
Pharmacy and medical claims data for MS patients (N = 5,232) were extracted for 
2008 from a pharmacy beneﬁt management (PBM) company. The two study popula-
tions included: 1) patients who received therapy from a specialty pharmacy, and 2) 
those who received therapy from retail pharmacies. Adherence was measured using a 
Medication Possession Ratio (MPR), with patients considered adherent for MPR ≥ 
80%. Nonparametric statistical tests and multivariate log-linear regression analyses 
were used to determine differences between the two populations. RESULTS: The 
results suggest that MS patients receiving therapy from a specialty pharmacy have 
signiﬁcantly lower total medical costs than patients who receive therapy from a retail 
pharmacy [−0.18; 95% CI −0.33, −0.02]. Overall, specialty pharmacy MS patients 
tended to have lower total medical costs, IP costs and ofﬁce visits as compared to 
retail patients. CONCLUSIONS: DMD therapy is considered an effective treatment 
for relapsing-remitting MS patients. Specialty pharmacies often have additional patient 
care services that help the patient manage their therapy more effectively. This study 
demonstrates that MS patients taking a DMD who are medically managed in a spe-
cialty pharmacy setting can achieve lower medical costs. This has signiﬁcant implica-
tions for insurers and patients.
PND8
APPROACH TO MATCHING ALZHEIMER’S DISEASE PATIENTS AND 
THEIR SPOUSES TO ASSESS CAREGIVER BURDEN IN AN 
ADMINISTRATIVE CLAIMS DATABASE
Brixner D1, McAdam-Marx C1, Perlman D2, Van Den Bos J2
1University of Utah, Salt Lake City, UT, USA, 2Milliman, Inc, Denver, CO, USA
OBJECTIVES: To present a methodology for matching Alzheimer’s disease (AD) 
patients and their spouses to non-AD couples using an administrative claims database 
to assess caregiver burden. METHODS: Data were extracted from MarketScan claims 
databases from January 1, 2002--December 31, 2008. Patients with an AD ICD-9 
diagnosis code and with a spouse in the database were eligible for matching; their 
index date was the date of ﬁrst AD diagnosis. Couples with no AD diagnoses were 
eligible as controls and were matched 1:1 to AD couples based on patient and spouse 
birth years ± 3 years, index date ± 1 year (deﬁned as eligibility midpoint), gender, and 
CDPS risk adjuster score prior to index date. All subjects had continuous eligibility 
12+ months pre- and post-index date. RESULTS: Of 12,476 AD patients with spouses 
who met all inclusion criteria, 12,370 matched to a control couple. AD couples who 
did not match often had a greater age difference than available control couples. More 
AD patients and spouses utilized AD medications, antidepressants, anxiolytics, and 
antipsychotics pre-index date than their controls (p < 0.05). AD patients had a higher 
pre-index prevalence of non-AD dementia, anxiety, and psychosis than control 
patients (p < 0.001). AD spouses had increased antidepressant use post index 
(p < 0.001); control spouses showed no change. AD patients had a greater increase in 
total costs post index date than control patients (p < 0.001); no difference in total 
cost was observed between AD and control spouses, whose increases were similar to 
control patients. CONCLUSIONS: Matching on a risk adjuster score resulted in 
similar rates of chronic conditions between case and control couples but may have 
limited the ability to detect whether AD impacts spouse health care resource use. 
However, signiﬁcant differences in prevalence of dementia and other mental health 
conditions were noted for AD patients, and an increase in antidepressant use suggests 
such a trend.
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HEALTH CARE COSTS STRATIFIED BY EPILEPSY SEVERITY IN A US 
COMMERCIALLY INSURED SETTING
Richy F1, Banerjee S2, Makaroff L2, Bancel C3, Clark C3, Gervasoni C4, Lilliu H1
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Inc., Atlanta, GA, USA, 4Keyrus nv, Waterloo, Belgium
OBJECTIVES: To measure health care costs related to epilepsy severity using real-life 
claims data (Pharmetrics®, IMS, USA) in a representative sample from a U.S. commer-
cially-insured population. METHODS: The observation period ranged from January 
2006-December 2007. Patients with at least two diagnoses of epilepsy before the 
observation period and at least two claims for anti-epileptic drugs (AEDs) during the 
observation period were included. As Pharmetrics® does not report data on disease 
severity, the number of epilepsy-related emergency room visits over two years (0, 1, 2, 
≥3) was used as a proxy. Covariates included age, gender, region, epilepsy-type, number 
of co-morbidities, concomitant AEDs, and treatment duration. Annualized costs were 
split into AED medications and non-AED costs. Non-AED costs included non-AED 
medications and ‘other’ costs including emergency room visits, hospitalizations, and 
physician visits. RESULTS: A total fo 9163 patients were included, with 14% in the 
most severe category (≥3 ER visits). Total annualized costs ranged from US$6,000 to 
$33,000 depending on disease severity. AED costs were not linked to severity; however 
‘other costs’ increased disproportionately with disease severity. In the unadjusted 
analysis, mean annualized AED, non-AED medication and ‘other’ costs were $2,513, 
$1,276 and $2,522, respectively, for those with no ER visits and $3,279, $3,457 and 
$26,270, respectively, for those with ≥3 ER visits. The rise in ‘other’ costs with severity 
was mainly attributable to hospitalization costs. In the adjusted analysis, the difference 
between AED and ‘other’ costs increased signiﬁcantly with epilepsy severity, number 
of co-morbidities, and age, whereas it decreased with improved AED compliance. 
CONCLUSIONS: Non-AED treatment costs increased disproportionately with epi-
lepsy severity, driven mainly by hospitalization. AED medication costs were not related 
to disease severity. This analysis suggests cost savings may be achieved through targeted 
strategies and improvement of patient compliance in cases of severe epilepsy.
